510 related articles for article (PubMed ID: 30569186)
21. Safety and Efficacy of [
Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
[No Abstract] [Full Text] [Related]
22. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
[TBL] [Abstract][Full Text] [Related]
23. New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC.
Rosar F; Maus S; Schaefer-Schuler A; Burgard C; Khreish F; Ezziddin S
Clin Nucl Med; 2023 May; 48(5):433-434. PubMed ID: 36758550
[TBL] [Abstract][Full Text] [Related]
24. 225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
Rosar F; Burgard C; Rohloff LV; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S
Clin Nucl Med; 2024 Jul; 49(7):621-629. PubMed ID: 38769643
[TBL] [Abstract][Full Text] [Related]
25. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [
Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J
J Nucl Med; 2023 Jul; 64(7):1024-1029. PubMed ID: 36997329
[TBL] [Abstract][Full Text] [Related]
26. Dual-Time-Point Posttherapy
Straub M; Kupferschläger J; Serna Higuita LM; Weissinger M; Dittmann H; la Fougère C; Fiz F
J Nucl Med; 2023 Sep; 64(9):1431-1438. PubMed ID: 37414446
[No Abstract] [Full Text] [Related]
27. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
28. 177 Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer.
Qu G; Hua Q; Li H; Zhang Y; Chen Y
Clin Nucl Med; 2024 Feb; 49(2):152-153. PubMed ID: 38170913
[TBL] [Abstract][Full Text] [Related]
29. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [
Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38635050
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of early prostate specific antigen changes after [
Giovanella L; Garo ML; Cuzzocrea M; Paone G; Herrmann K
Eur J Clin Invest; 2023 Sep; 53(9):e14014. PubMed ID: 37194605
[TBL] [Abstract][Full Text] [Related]
31. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
Hartrampf PE; Mihatsch PW; Seitz AK; Solnes LB; Rowe SP; Pomper MG; Kübler H; Bley TA; Buck AK; Werner RA
J Nucl Med; 2023 Aug; 64(8):1272-1278. PubMed ID: 37290794
[TBL] [Abstract][Full Text] [Related]
32. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
33. Comparison of quantitative whole body PET parameters on [
Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS
Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135
[TBL] [Abstract][Full Text] [Related]
34. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
35. Real-world Outcomes and Predictive Biomarkers for
Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
[TBL] [Abstract][Full Text] [Related]
36. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
Shagera QA; Karfis I; Sideris S; Guiot T; Woff E; Martinez-Chanza N; Roumeguere T; Gil T; Flamen P; Artigas C
Clin Nucl Med; 2023 Sep; 48(9):775-780. PubMed ID: 37385221
[TBL] [Abstract][Full Text] [Related]
37. Increased PSMA Expression in 177 Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide : A Potential Game-Changer.
Aggarwal P; Kaur K; Sood A; Periasamy K; Nagi S; Mittal BR
Clin Nucl Med; 2023 May; 48(5):411-413. PubMed ID: 36728226
[TBL] [Abstract][Full Text] [Related]
38. Promising Therapeutic Activity of 177 Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer : A Pilot Experience.
Satapathy S; Yadav MP; Ballal S; Sahoo RK; Bal C
Clin Nucl Med; 2024 Feb; 49(2):131-137. PubMed ID: 38049970
[TBL] [Abstract][Full Text] [Related]
39. Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience.
Celen YZ; Elboga U; Sahin E; Kus T; Okuyan M; Cayirli YB; Erturhan S; Cimen U
Hell J Nucl Med; 2023; 26(3):187-193. PubMed ID: 38085834
[TBL] [Abstract][Full Text] [Related]
40. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
Santo G; Di Santo G; Zelger B; Virgolini I
Nuklearmedizin; 2024 Jun; 63(3):219-220. PubMed ID: 38190993
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
